eFFECTOR Therapeutics, a leader in selective translation regulator inhibitors (STRIs) for cancer treatment, reported financial results for Q4 and full-year 2022, along with a corporate update. The company's highly selective MNK inhibitor, tomivosertib (eFT508), can activate T-cells and expand central memory T-cells to enhance anti-tumor immune activity. eFFECTOR's wholly-owned potent and selective inhibitor, zotatifin (eFT226), can downregulate oncoproteins and drive tumor growth and resistance. The enrollment in the expanded ECBF+A cohort was completed, and data is expected in H1 2023. Topline data for Phase 2b KICKSTART trial in NSCLC is anticipated in H2 2023, while the cash runway is expected to be available until Q1 2024. The CEO and President of eFFECTOR, Steve Worland, Ph.D., said, "We look forward to reporting these data and advancing both assets into late-stage development."